Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2946 - Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Clinical Research

Tumour Site

Presenters

Valentina Boni

Citation

Annals of Oncology (2018) 29 (suppl_8): viii133-viii148. 10.1093/annonc/mdy279

Authors

V. Boni1, J. Garcia-Corbacho2, P.A. Ott3, D.C. Cho4, K.A. Autio5, N. Uboha6, A.I. Spira7, R. Humphrey8, M. Will8, A. Naing9, F. Thistlethwaite10, E.G..E. de Vries11, H. Arkenau12

Author affiliations

  • 1 Medical Oncology, START Madrid-CIOCC HM Hospital Sanchinarro, 28050 - Madrid/ES
  • 2 Medical Oncology, Hospital Clinic Barcelona, Barcelona/ES
  • 3 Center For Immuno-oncology, Dana-Farber Cancer Institute, Boston/US
  • 4 Department Of Medicine, New York University Langone Medical Center, New York/US
  • 5 Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 6 Carbone Cancer Center, University of Wisconsin, Madison/US
  • 7 ,, Virginia Cancer Specialists, Fairfax/US
  • 8 Medical Oncology, CytomX Therapeutics, South San Francisco/US
  • 9 Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 10 Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 11 Medical Oncology, University Medical Center Groningen, 9700 RB - Groningen/NL
  • 12 Scri, Sarah Cannon Research Institute SCRI UK, W1G 6AD - London/GB
More

Resources

Abstract 2946

Background

Antibodies (Abs) against programmed cell death ligand-1 (PD-L1) have improved survival in many types of cancer when used as monotherapy. However, anti–PD-L1 agents can be associated with high-grade immune-related adverse events (irAEs), particularly when used in combination with other anticancer agents. CX-072 is an anti–PD-L1 Probody™ therapeutic (Pb-Tx) designed to be preferentially activated by proteases in the tumor microenvironment and not in healthy tissue. Preclinically, Pb-Tx exhibited anticancer activity of the parent Ab with reduced toxicities in models of autoimmunity.

Methods

In parts A and A2 of the ongoing phase 1/2 Probody Clinical Assessment In Man (PROCLAIM)-CX-072 study (NCT03013491), CX-072 monotherapy is evaluated in a dose-escalation cohort of pts with advanced, heavily pretreated solid tumors. Part A2 required PD-L1-positive tumors and paired biopsies. Eligible pts were PD-1, PD-L1, and CTLA-4 inhibitor naive, with immunotherapy (IMT) unavailable as a standard of care. CX-072 is given every 14 days in cohorts of intravenous doses ranging from 0.03-30 mg/kg.

Results

As of April 20, 2018, part A/A2 had enrolled 37 pts. Pts had a median (range) of 3 (1-13) prior anticancer treatments. 14 (37.8%) pts are still on treatment at time of data cut. Median (range) time on treatment was 2.1 months (1-10). One DLT was observed (grade 3 febrile neutropenia; 3 mg/kg); MTD was not reached. Grade 3-4 treatment-related events were observed in 4 (10.8%) pts. irAEs with reversible grade 3 events occurred in 3 patients: thrombocytopenia, aminotransferase increases, and dyspnea. Two subjects discontinued CX-072 due to AEs. Across all dose levels, best response based on investigators’ assessment in 23 evaluable pts included 2 partial response (thymoma, 3 mg/kg; TNBC, 10 mg/kg), 10 stable disease, and 11 progressive disease.

Conclusions

Preliminary data suggest that CX-072 demonstrates the characteristics of an antibody prodrug with antitumor activity and an acceptable safety profile in heavily pretreated pts with IMT-naive solid tumors. These data warrant further exploration of CX-072 as monotherapy and in combination with other anti-cancer agents.

Clinical trial identification

NCT03013491.

Legal entity responsible for the study

CytomX Therapeutics, Inc.

Funding

CytomX Therapeutics, Inc.

Editorial Acknowledgement

Editorial support was provided by Andrew Occiano (ApotheCom, San Francisco, CA).

Disclosure

P.A. Ott: Research grant: BMS, Merck, Celldex, MedImmune, CytomX, ArmoBiosciences, Neon Therapeutics; Consulting: BMS, Merck, Celldex, CytomX, Roche/Genentech, Pfizer, Novartis, Neon Therapeutics; Nonremunerative positions of influence: NCCN melanoma guidelines board member. D.C. Cho: Consulting: BMS, Pfizer, Exelixis, Genentech, Prometheus. K.A. Autio: Research funding: CytomX, Pfizer, Lilly, GSK, Merck, ARMO Biosciences. N. Uboha: Consulting: EMD Serono, Lilly, FlatIron, GLG. A.I. Spira: Research grant: AbbVie; Consulting: AbbVie. R. Humphrey, M. Will: Employee: CytomX. A. Naing: Research funding: NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor, Amplimmune, ARMO Biosciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Baxter (spouse). F. Thistlethwaite: Research grant: Novartis; Consulting: Pfizer, BMS, Octimet, Achilles Therapeutics, Evelo Biosciences; Honorarium: Novartis; Speakers' bureau: BMS. E.G.E. de Vries: Research grant (institution): Amgen, Genentech, Roche, Chugai, Synthon, CytomX, Nordic Nanovector, Regeneron, G1 Therapeutics, AstraZeneca, Radius Health; Consulting (institution): Pfizer, Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.